LGT Fund Management Co Ltd. Has $1.05 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

LGT Fund Management Co Ltd. lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 112.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 1,870 shares of the company’s stock after purchasing an additional 990 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in IDEXX Laboratories were worth $1,051,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Empowered Funds LLC boosted its position in IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after buying an additional 95 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth approximately $265,000. Jump Financial LLC raised its stake in shares of IDEXX Laboratories by 1,006.4% in the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after acquiring an additional 5,032 shares during the last quarter. Cary Street Partners Financial LLC bought a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $164,000. Finally, Sei Investments Co. boosted its holdings in shares of IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after acquiring an additional 82,755 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $563.57 on Monday. The stock’s fifty day simple moving average is $555.09 and its 200-day simple moving average is $603.76. The firm has a market capitalization of $44.46 billion, a PE ratio of 41.50, a price-to-earnings-growth ratio of 3.08 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue was up 14.3% on a year-over-year basis. During the same period last year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 25th. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.